Kymera Therapeutics Inc. (KYMR) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Kymera Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Kymera Therapeutics Inc. (KYMR) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $9.8B. It trades at $122.51, up 4.20% today. 16 analysts' average target of $142.19 implies +16.1% from today's price. Kronos AI's 30-day forecast is −14.8% (1 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $142.19 |
| Low – high | $112.00 – $180.00 |
| Analysts | 16 |
| Upside to average | +16.1% |
Kronos AI 30-day forecast
| Expected close | $100.23 (−14.8%) |
| Likely range | −20.2% … −6.2% |
| As of | 2026-10-27 |
Quality scores
Not scored: the financial data for this listing is incomplete.
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Halal Health Care stocks · Zakat calculator · Purification calculator